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Abstract
Introduction: Proinflammatory cytokines and regulatory t cells (tregs) are considered as import-
ant factors involved in autoimmunity development especially in rheumatoid arthritis (ra).
Aim of the study: to investigate the frequency of peripheral blood tregs and related cytokines in ra 
patients and to determine the possible correlation between treg percentage and interleukin 6 (il-6) and 
transforming growth factor β1 (tgf-β1) as indicators in assessment of treg function and mechanisms 
preceding autoimmunity in ra.
Material and methods: thirty-seven iranian ra patients with a moderate (3.2-5.1) disease activity 
score (das) and the same number of healthy age- and sex-matched individuals were enrolled. frequen-
cy of peripheral blood tregs (Cd4+foxP3+Cd25high) was determined by flow cytometry. serum levels 
of il-6 and tgf-β1 and their expression levels in peripheral blood mononuclear cells (PBMCs) were 
evaluated by elisa and Q-PCr, respectively.
Results: rheumatoid arthritis patients showed significantly lower peripheral blood treg frequencies 
compared to healthy individuals. additionally, treg (%) showed a significant inverse correlation be-
tween serum concentrations of il-6 and mrNa expression of PBMCs, whereas there was no significant 
correlation between treg (%) and tgf-β1 levels.
Conclusions: the current study revealed that treg numbers were reduced in peripheral blood of ra 
patients. this reduction inversely correlated with il-6 levels, which may lead to persistent autoimmune 
and inflammatory conditions in ra patients.
Key words: rheumatoid arthritis, tgf-β1, il-6, regulatory t cells.
(Centr eur j immunol 2018; 43 (3): 281-288)
Introduction
Rheumatoid arthritis (RA) is a chronic and systemic 
autoimmune disease characterized by joint inflammation 
eventually leads to destruction of cartilage and bone [1]. 
Although what precisely causes RA is not fully understood 
[2], studies highlight the potential importance of T cell 
subsets and cytokines in both driving and suppressing in-
flammation in RA [3, 4]. Regulatory T cells (Tregs) have 
an important role in the control of auto-reactivity and the 
pathogenesis of RA. The particular function of Treg cells 
(CD4+FoxP3+CD25high cells) is preventing autoimmunity 
either via the suppression of other autoreactive lympho-
cytes through cell-cell interactions or via secretion of reg-
ulatory cytokines such as transforming growth factor β1 
(TGF-β1) [5, 6].
The cytokine network is complex in RA and includes 
various cytokines presenting in both synovial joints and 
peripheral blood [7, 8]. Transforming growth factor β1 
is one of the cytokines in RA secreted from various cell 
types. This cytokine regulates proliferation and differenti-
ation of T cell subsets [9] and has a modulatory effect on 
inflammatory cells [10].
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Furthermore, IL-6 is one of the most prominent inflam-
matory cytokines, which has pleiotropic activities in RA 
pathogenesis and its systemic manifestations [11]. Overpro-
duction of IL-6 from several cells results in maturation of 
B cells, and consequently production of auto-antibodies as 
well as enhanced migration of inflammatory cells into the 
joint and also stimulates production of harmful compounds 
from chondrocytes and other immune cells [12, 13]. Addition-
ally, IL-6 has a pivotal role to determine T cell fate in collab-
oration with other cytokines [14]. There is cross-talk between 
TGF-β1 and IL-6 signaling pathways [15]; however, a novel 
hypothesis has been proposed that they act in a dose-depen-
dent manner, and therefore polarization as well as plasticity of 
T cells is changed in the mentioned cytokine milieu and may 
be one of the factors responsible for autoimmunity develop-
ment [16]. in vitro studies showed that IL-6 and TGF-β1 sig-
naling promotes FoxP3 degradation, consequently resulting in 
imbalance in the population of Treg/Th17 [17].
Related information about Treg frequency in the pe-
ripheral blood of RA patients is controversial. Thus the 
current investigation was carried out to evaluate the fre-
quency of peripheral Tregs (CD4+FoxP3+CD25high) and 
correlation with serum level and mRNA expression of 
IL-6 and TGF-β1 between RA patients in comparison with 
healthy individuals.
Material and methods
Patient selection
In this study, 37 patients with RA and the same number 
of age- and sex-matched healthy individuals were recruited 
from the Rheumatology Clinic of Imam Ali in Shahrekord, 
Iran. In all RA patients, the diagnosis was established with 
ACR/EULAR diagnostic criteria for RA 2010 [18]. In this 
cross-sectional study, the patient conditions were all chronic 
and they were selected as having moderately active disease 
(3.2-5.1) on the basis of disease activity score 28 (DAS28). 
Written consent was obtained from all participating indi-
viduals prior to sample collection. The study was approved 
by the ethical committee of Sharekord University. Rheuma-
toid arthritis patients were treated with disease-modifying 
anti-rheumatic drugs (DMARDs) and steroids. Mean doses 
of medications for RA are presented in Table 1.
Sample preparation
After taking 6 ml of whole blood with K
3
EDTA, the 
samples were immediately transferred to the laboratory on 
ice. Small aliquots of fresh whole blood were separated for 
flow cytometric analysis of Tregs. Then in order to isolate 
PBMCs, blood was mixed with the same volume of cold 
PBS. Diluted blood was gently transferred to a sterile tube 
containing Ficoll Histopaque-1077 (Sigma). The PBMC 
ring was separated by washing twice with cold PBS by 
30 min centrifugation at 400 g, 4°C. Total RNA was 
quickly isolated from PBMCs using total RNA extraction 
TRIzol Reagent (Invitrogen). Quality and quantity of RNA 
were determined by a spectrophotometer (NanoDrop ND-
1000, Thermo Scientific) and gel agarose electrophoresis 
(observing distinct 28S and 18S ribosomal bands).
Real time-PCR
For cDNA synthesis 0.5 µg of total RNA was used 
for the reverse transcription reaction, which was carried 
out using the Revert Aid First Strand cDNA Synthesis Kit 
(Thermo Scientific, Fermentas) according to the manufac-
turer’s instructions. The quantification of mRNA expres-
sion of cytokines was performed using Rotor-Gene TM 
6000 (Corbett). Real time-PCR (RT-PCR) reactions were 
performed in a total volume of 25 µl containing 2 µl of 
synthesized cDNA as a template, 12.5 µl of 2x Rotor-Gene 
Probe PCR Master Mix (Qiagen, Germany), 500 nM of 
each primer and 250 nM of the TaqMan-probe (FAM, 
TAMRA), 3 µl, and finally DNase/RNase free water was 
added to make a total volume of 25 µl. The amplification 
program included a pre-heating step (10 min at 94°C), 
a denaturation step (94°C for 15 s) and an annealing/ex-
tension step (60°C for 60 s). The mRNA expression of 
Table 1. Mean doses of DMARD therapy in RA patients
Medication Mean dose
Methotrexate (MTX) 7.5-15 mg/wk
Pprednisone (steroid) 5-10 mg/d
Hydroxychloroquine 200-400 mg/d
Sulfasalazine 1-2 g/d
Table 2. Sequences of primers and probes
Sequence Gene 
5’- CCGCCGCCCGTCCACACCCGCC-3’
5’-AGCCTCGCCTTTGCCGA-3’
5’-CTGGTGCCTGGGGCG-3’
β-Actin 
Probe
β-Actin 
Forward
β-Actin 
Reverse
5’- TGTTACTCTTGTTACATGTCTCCTTTCTCAGGGCT -3’
5’- GGTACATCCTCGACGGCATCT -3’
5’- GTGCCTCTTTGCTGCTTTCAC -3’
IL-6 Probe
IL-6 
Forward
IL-6 
Reverse
5’- CTGCTGGCACCCAGCGACTCG -3’
5’- CAGCAACAATTCCTGGCGATA -3’
5’- AAGGCGAAAGCCCTCAATTT -3’
TGF-β1 
Probe
TGF-β1 
Forward
TGF-β1 
Reverse
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cytokines was normalized to β-actin (housekeeping gene) 
and relative quantification was determined using the 2-ΔΔCt 
method. The sequence of oligonucleotides of IL-6, TGF-β1 
and β-actin primers and probes is shown in Table 2.
Flow cytometry
Antibodies used for Treg cell assessment in flow cy-
tometry were purchased from BD Pharmingen (Becton 
Dickinson, San Jose, CA, USA, BD); anti-CD4 conjugat-
ed to PE-Cy5, anti-CD25 (alpha chain of IL-2 receptor) 
conjugated to allophycocyanin (APC) and anti-FoxP3 con-
jugated to phycoerythrin (PE). The staining process was as 
follows: small aliquots (100 µl) of whole blood containing 
K
3
EDTA were incubated for 30 min with anti-CD4 and 
anti-CD25, and red blood cells were lysed subsequently. 
After surface staining, cells were fixed and permeabilized 
using the Fixation/Permeabilization Kit (BD, Human 
FoxP3 Buffer Set) for intracellular staining. Briefly, cells 
were fixed in FoxP3 Buffer A, for 15 minutes at room tem-
perature (RT) and the cells were washed. To permeabilize 
cells they were incubated for 30 minutes in human FoxP3 
Buffer B. Finally, after washing, cells were stained with 
10 µl of PE Mouse anti-Human FoxP3. All of the process 
was protected from light.
Firstly gating was done on CD4+ cells then detection of 
CD25high, FoxP3+ within the population followed. Isotype 
controls were used to discriminate unstained cells. Anal-
ysis was performed using a flow cytometer (PARTEC, 
Münster, Germany). The results were analyzed using Flow 
Jo software version 7.6.1 (Tree Star, Ashland, OR, USA).
Measurement of serum IL-6 and (active) 
TGF-β1 concentration by ELISA
Serum concentrations of IL-6 and TGF-β1 were deter-
mined with an ELISA kit (Quantikine; R&D, Minneapolis, 
MN). These assays were performed according to methods 
outlined in the manufacturer’s instructions. To activate 
latent TGF-β1, HCL/NaOH was added to samples in the 
concentration listed in the instructions. Thereafter, we sep-
arately for each plate added 50 and 100 µl of activated 
TGF-β1 and IL-6 of samples per well, respectively. The 
plates were incubated for 2 hours at RT. After aspirating 
and washing each well three times, 100 µl for TGF-β1 and 
200 µl for IL-6 conjugate antibody were added to each well 
and the plates were incubated for 2 hours at RT. We re-
peated the aspiration/wash three times and added 200 ml of 
substrate solution to each well and incubated plates away 
from lights for 30 minutes. Finally, we added stop solution 
and absorbance in each well was measured using a spec-
trophotometric plate reader at a wavelength of 450 nano-
meters (Biohit, BP800, Finland). Serum levels of TGF-β1 
and IL-6 were calculated from a linear regression standard 
curve in logarithm scales.
Statistical analysis
All statistical analyses were done with SPSS version 
21 (SPSS Inc, Chicago, Illinois, USA). At first normality 
tests were used to determine whether a data set is well 
modeled by a normal distribution. The differences between 
patients and healthy groups as well as correlation for Treg 
percentage and cytokine levels were analyzed using the 
Table 3. Laboratory investigations of RA patients and 
healthy individuals included in this study (n = 37) 
 RA patients Healthy 
individuals 
p-value
Mean ±SD Mean ±SD
Age 46.9 ±7.6 44.5 ±8.8 NS
WBC count (103 cell/µl) 7750 ±2390 5950 ±830 **
Lymphocyte count 
(109/l)
2200 ±630 2050 ±370 *
ESR (mm/h) 45.6 ±23.55 9.8 ±5.35 ***
CRP (mg/l) 21.3 ±7.8 < 4 ***
Rheumatoid factor  
(IU/ml)
83.4 ±60.2 – ***
Anti-citrullinated peptide 
antibody (IU/ml)
60.5 ±43.3 – ***
Disease activity score 
(DAS28)
4.2 ±0.38 – –
NS – not significant; *p < 0.05, **p < 0.01, ***p < 0.001
Table 4. Data and statistical interpretations of investiga-
tion
RA 
patients
Healthy 
individuals
p-value
Mean ±SD
Treg percentage 1.58 ±0.24 1.85 ±0.3 **
Serum IL-6 (pg/ml) 28.1 ±9.1 4.2 ±0.8 ***
Serum TGF-β1 (ng/ml) 41.2 ±10.43 29.8 ±8.96 ***
mRNA expression in 
PBMCs (fold change)
 Mean ±SEM
IL-6 1.3 ±0.21 0.57 ±0.21 ***
TGF-β1 1.35 ±0.24 2.15 ±0.37 **
Correlation Correlation coefficient (r)
Tregs (%) and serum IL-6 0.47 **
Tregs (%) and IL-6 
expression in PBMCs
0.37 **
**p < 0.01, ***p < 0.001
Central European Journal of Immunology 2018; 43(3)
Majid Khoshmirsafa et al.
284
Mann-Whitney and Spearman test, respectively. After-
wards, p values less than 0.05 were considered significant 
at the level of the 95% confidence interval. Results for 
cytokine expression and frequencies of Treg cells were 
presented using Prism software 6.01 (Graph Pad, La Jolla, 
California) as means ±standard error of mean (SEM) and 
standard deviation (SD), respectively.
Results
In this study, 37 patients (32 females and 5 males) 
with RA and the same number (31 females and 6 males) 
of healthy individuals were included. The descriptive data, 
laboratory finding and statistical interpretation of investi-
gation in RA patients and healthy individuals are shown in 
Tables 3 and 4.
RT-PCR results
Interleukin 6 expression was significantly higher in 
PBMC specimens of RA patients compared with healthy 
individuals (p < 0.001). The mean ± SEM of IL-6 expres-
sion in RA patients and healthy individuals were 1.3 ±0.21 
and 0.57 ±0.21, respectively. Consequently, IL-6 mRNA 
expression in RA patients showed a 2.6-fold difference in 
comparison with healthy individuals. In addition, TGF-β1 
expression was significantly lower in PBMC specimens of 
RA patients compared with healthy individuals (p < 0.01). 
The mean ± SEM of TGF-β1 expression in RA patients 
and healthy individuals was 1.35 ±0.24 and 2.15 ±0.37, 
respectively. Therefore, the TGF-β1 mRNA expression in 
RA patients showed a 0.63-fold difference in comparison 
with healthy individuals (Fig. 1A, B).
ELISA results
The mean ± SD of the TGF-β1 in serum of RA patients 
and healthy individuals was 41.2 ±10.43 and 29.8 ±8.96 
ng/ml, respectively. This level was significantly higher in 
RA patients than in healthy individuals (p < 0.001). Addi-
tionally, the level of IL-6 was significantly higher in the 
RA patients than in healthy individuals (28.1 ±9.1 vs. 4.2 
±0.8 pg/ml) (p < 0.001) (Fig. 2C, D).
Treg cell frequencies
The frequency of Tregs (CD4+FoxP3+CD25high) was 
significantly lower (p < 0.01) in the RA patients (1.58 
±0.24) compared to healthy individuals (1.85 ±0.3). Also, 
the percentage of Tregs showed a significant inverse cor-
relation with serum IL-6 (r = 0.47, p < 0.01) and mRNA 
IL-6 expression in PBMCs (r = 0.37, p < 0.01) of RA pa-
tients. The inverse correlation was stronger between Treg 
percentage and serum IL-6 levels (Fig. 1E, F). However, 
there was no significant correlation between frequency of 
Tregs and TGF-β1 (data not shown).
Discussion
Deregulation of tolerance mechanisms plays a pivotal 
role in the pathogenesis of rheumatoid arthritis. Further-
more, the persistent immune dysfunction with systemic 
inflammation suggests an imbalance in the cytokine secre-
tion and frequency of Tregs.
In this study we investigated the frequency of regu-
latory T cells, then determined possible relationships be-
tween their frequency and cytokine production in moder-
ately active RA patients compared to healthy individuals. 
At first, flow cytometric results of RA patients revealed 
a significantly lower percentage of circulating CD4+Foxp3+ 
CD25high Tregs as compared to healthy controls. Similarly, 
our findings are consistent with most studies, although the 
authors have presented various conclusions [19-21]. A ma-
jor differences between studies could be a result of the 
definition of Tregs in flow cytometric gating patterns [22-
24]. However, some studies have suggested that regulatory 
T cells are recruited to sites of inflammation to modulate 
disease, resulting in a relative reduction in the population 
of peripheral blood Tregs. Reports indicating an increased 
number of Tregs in synovial fluid support this hypothe-
sis [25]. In addition, some studies have shown increased 
Tregs’ spontaneous apoptosis in active RA [26, 27].
Contrary to our findings there are reports indicating 
higher Treg levels in RA peripheral blood, but they as-
sessed different levels of CD25 T cells, which could ac-
count for the variation in the results [20, 28]. Nevertheless, 
some ex vivo studies on CD4+T cells showed that only high 
CD25 expressing T cells exert inhibitory effects. In con-
trast, intermediate expressing CD25 T cells are effector 
cells [29, 30].
We next investigated IL-6 and TGF-β1 in two frac-
tions: serum levels and mRNA expression in PBMCs. 
We observed significantly higher IL-6 mRNA expression 
of PBMCs and serum levels in RA patients compared to 
healthy individuals. Although the level of TGF-β1 was 
higher in serum, mRNA expression of PBMCs was lower 
than in the healthy group.
Interleukin 6 is produced predominantly by macro-
phages and fibroblasts, but the exact source and mecha-
nisms leading to IL-6 increase in the serum of RA patients 
are still unclear. The effects of IL-6 on disease activity, 
symptom persistence and inflammation have been former-
ly established in the pathogenesis of RA [31, 32]. There-
fore, several studies have documented that an elevated 
IL-6 level is in correlation with physical damage, disease 
activity (DAS) and erythrocyte sedimentation rate (ESR) 
[11, 33, 34].
Wang et al. proposed that an inflammatory envi-
ronment made Tregs unstable and they are converted to 
pathological T cells such as Th17 [35]. Nevertheless, our 
results also demonstrated that Treg percentages showed 
a positive inverse correlation with serum concentration of 
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Fig. 1. Level of serum concentration, mRNA expression and the correlation of IL-6 and TGF-β1 in RA patients and 
healthy controls. IL-6 and TGF-β1 mRNA expression in PBMCs was analyzed by real-time quantitative-PCR (mean 
±SEM). The results were normalized to β-actin (A, B). Serum concentrations of IL-6 and TGF-β1 were measured by 
ELISA. Data are expressed as means ±SD (C, D). Correlation coefficient and regression line of peripheral blood Tregs 
(%) with IL-6 serum levels (E) and mRNA expression in PBMCs (F) were represented as scatter plots. Spearman’s cor-
relation analysis was performed. There was no significant correlation between Treg and TGF-β1 (not shown)
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IL-6 and its mRNA expression in PBMCs. This correlation 
is more robust in the serum fraction than mRNA expres-
sion of PBMCs. In this way, investigations showed that 
cytokine profile is not appropriate for differentiation and 
survival of Treg cells in peripheral blood of RA patients, 
and subsequently it leads to a decrease in Treg numbers. 
It seems this circumstance may facilitate establishment of 
the autoimmunity process [36].
Transforming growth factor β1 is one of the most 
prominent immune suppressor cytokines that is secreted by 
almost all immune cell lineages, including T, B, dendrite 
cells, macrophages, as well as fibroblasts [9]. Transform-
ing growth factor β1 negatively regulates the proliferation, 
differentiation and death of different cell types; therefore 
the most critical function of TGF-β1 is prevention of aber-
rant responses leading to autoimmunity [9, 10]. Our study 
showed a significantly higher serum level of TGF-β1 in RA 
patients compared with healthy controls. However, mRNA 
expression of TGF-β1 was markedly lower in PBMCs of 
RA patients. Several studies have suggested that elevated 
TGF-β1 in rheumatoid sera and also synovial fluids may 
suppress joint inflammation by inhibiting RANTES secre-
tion [37]. In addition, higher TGF-β1 levels in serum and 
synovial tissue were found in patients with rheumatoid ar-
thritis compared with osteoarthritis patients [38]. On the 
other hand, some reports showed that TGF-β1 accounts 
Fig. 2. Flow cytometric analyses of peripheral blood Tregs in RA patients and healthy controls. CD4 positive cells were 
gated from lymphocyte population (A). Intracellular FoxP3 and the expression of surface CD25 were indicated as dot 
plots (Q2) for healthy controls (B) and RA patients (C). Data are shown as mean and SD in scatter plot, representing 
significant difference of Treg (%) between healthy controls and RA patients (D)
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for increasing the expression of proinflammatory cytokines 
and metalloproteinase-1 (MMP-1) by synovial fibroblasts 
and promotes joint destruction by induction of aggrecanase 
[39]. These contradictory functions of TGF-β1 might de-
pend on dose and site of effect. Some animal experiments 
have demonstrated that systemic administration of TGF-β1 
to mice inhibits collagen-induced arthritis (CIA), whereas 
its local administration to joints induces synovitis and ex-
acerbates the disease activity. Similarly, blocking endoge-
nous TGF-β1 by systemic injection of anti-TGF-β1 anti-
body aggravates CIA in mice, whereas the local blockade 
of TGF-β1 ameliorates continuous inflammation [37, 40].
The Q-PCR results of TGF-β1 expression in PBMCs 
showed a decrease in RA patients which was scarcely 
described elsewhere. This finding could be a result of 
DMARD therapy, systemic inflammatory condition and 
immune cell infiltration, especially joint involvement. No 
association was found between serum levels and PBMCs’ 
mRNA expression of TGF-β1 with Treg frequency in RA 
patients. There are scant studies that have investigated in 
vivo the effect of TGF-β1 on Treg frequency, but numer-
ous in vitro studies have shown how TGF-β1 and IL-6 act 
together to promote the degradation of FOXP3 in Tregs.
Recent clinical studies showed that DMARD therapy 
would result in a reduction of IL-6 and other pro-inflam-
matory cytokines such as TNF-α in both serum and syno-
vial fluid, but in spite of DMARD therapy, these values 
remained higher in patients in comparison to healthy indi-
viduals [11]. In addition, in vitro studies demonstrated that 
methotrexate (MTX) induced more apoptosis in T cells 
than monocytes. Also, other studies have shown that the 
IL-6 level produced by monocytes was higher than T cells, 
but there were some recent in vitro observations that MTX 
induced the expression of pro-inflammatory cytokines such 
as IL-1 and IL-6 in a monocyte cell line; however, they 
were a small population in PBMCs [41]. Moreover, RA 
patients on combinational therapy (DMARD therapy plus 
biologic drugs) showed a smaller increase in pro-inflam-
matory cytokine levels compared to patients on DMARD 
therapy alone [42]. In summary, identification of a reliable 
and accessible biomarker for disease activity, its progres-
sion, and monitoring of patients is an attractive therapeu-
tic aim. It seems that the levels of some pro-inflammatory 
cytokines, for example, IL-6 produced by PBMCs, can be 
used as a biomarker to predict the status of treatment.
Conclusions
In summary, the present study showed that RA patients 
have a lower peripheral blood Treg percentage and higher 
serum levels of IL-6 and TGF-β1 than healthy individu-
als. We also found increased expression of IL-6 but not of 
TGF-β1 in PBMCs. Also, our results confirm that IL-6 in-
versely correlated with Treg frequency in peripheral blood. 
Further studies are needed to assay other cytokines and 
their molecular relationships with Treg frequency.
Limitations
In this study, in order to keep uniform the severity of 
disease, RA patients with similar activity (moderate group) 
were included based on DAS28. Nonetheless, this catego-
rization and also the impact of DMARD therapy do not 
coincide for all cases. Consequently, further research is 
needed to evaluate more accurately the correlation between 
Treg percentage and levels of IL-6 and TGF-β in all RA 
patients with different disease activities. Additionally, in 
order to avoid influencing the therapy at cytokine levels, 
early diagnosed RA patients with no treatment should be 
included in the future studies to more efficiently categorize 
patients.
the authors declare no conflict of interest.
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